ImpediMed (ASX:IPD) - Managing Director & CEO, Rick Carreon
Managing Director & CEO, Rick Carreon
Sourced: The Courier Mail
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medical software technology company ImpediMed’s (IPD) SOZO Digital Health Platform will be used in an AstraZeneca trial
  • The SOZO device non-invasively measures fluid status and tissue composition in less than 30 seconds
  • AstraZeneca will use the devices in its upcoming phase two trial of two drugs in heart failure patients with chronic kidney disease
  • ImpediMed will lease 175 SOZO devices across 20 countries for the use in the trial which will generate more than $2 million in revenue for the company
  • Shares have opened 14.3 per cent higher for 7.2 cents

Medical software technology company ImpediMed’s (IPD) SOZO Digital Health Platform will be used in an AstraZeneca trial.

SOZO is a bioimpedance spectroscopy (BIS) device which non-invasively measures fluid status and tissue composition in less than 30 seconds. It is FDA-cleared for heart failure as well as CE-Marked for heart failure and renal failure. 

AstraZeneca will use SOZO devices in its upcoming phase two trial of two drugs in heart failure patients with chronic kidney disease. The trial will commence in November and run for 18-months.

ImpediMed Senior Vice President Research and Development and Technology Dennis Schlaht said the new contract builds on the long-term commercial relationship with the pharmaceutical company.

“AstraZeneca has used ImpediMed’s BIS technology for a number of years to measure subjects’ fluid volumes in their clinical studies. With SOZO, they will be able to achieve the fluid measurement accuracy of gold standard dilution methods in a test that takes 30 seconds instead of up to 24 hours,” Dennis stated.

The trial will be conducted by a contract research organisation in 20 countries and use 175 SOZO devices.

The contract is on a software as a service basis, with monthly licence fees for each device, and it is expected to net ImpediMed in excess of $2 million.

ImpediMed Managing Director and CEO Richard Carreon said the company is extremely pleased that AstraZeneca has decided to use the company’s technology in the trial.

“Heart failure and chronic kidney disease are two of our three strategic focus areas, and this agreement provides further validation of the applicability of our technology in both patient populations. This endorsement of our technology is timely as the Company begins the launch of SOZO into the cardiology market,” Richard explained.

Shares have opened 14.3 per cent higher for 7.2 cents at 10:47 am AEST.

IPD by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…